Clinical Trial Update: Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating the safety and immunogenicity of CYT004-MelQbG10 vaccine with and without adjuvant in advanced malignant melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• CYT004-MelQbG10 Vaccine

Snippet

Sponsor: Cytos Biotechnology AG | Conditions: Malignant Melanoma | Phase 2 | Status: COMPLETED